Anne Prener, M.D., Ph.D., has more than 25 years of experience in leading companies and teams within biotechnology across several therapeutic areas with a special focus on rare diseases and gene therapy. She most recently served as the chief executive officer of Freeline Therapeutics, Ltd., a liver-directed gene therapy company, where she scaled the company from preclinical stage company to a fully integrated biotechnology organization, which included a broad, internally developed pipeline, two programs in clinical development and a commercial- scale, high-quality CMC and manufacturing platform. Prior to joining Freeline Therapeutics, she served as the chief executive officer of Gyroscope Therapeutics Ltd., a gene therapy company focused on eye diseases. Before that, Dr. Prener was vice president, clinical research hematology and global therapeutic area head of hematology at Baxalta. During her time there, three new major product approvals in both the U.S. and EU were secured along with a significant advancement in Baxalta’s hematology portfolio, including gene therapy for hemophilia. Earlier in her career, Dr. Prener held several positions of increasing responsibility at Novo Nordisk, most recently serving as senior vice president, hemophilia R&D portfolio where she was instrumental in building the hemophilia franchise to a portfolio of several late stage and commercial products.
Dr. Prener holds a Ph.D. in epidemiology and an M.D., both from the University of Copenhagen.